Cantor Fitzgerald Estimates Biohaven FY2026 Earnings

Biohaven Ltd. (NYSE:BHVN) – Investment analysts at Cantor Fitzgerald issued their FY2026 earnings per share estimates for Biohaven in a report issued on Monday, June 9th. Cantor Fitzgerald analyst P. Stavropoulos anticipates that the company will post earnings of ($6.65) per share for the year. Cantor Fitzgerald currently has a “Strong-Buy” rating on the stock. The consensus estimate for Biohaven’s current full-year earnings is ($8.90) per share.

A number of other research firms also recently issued reports on BHVN. Deutsche Bank Aktiengesellschaft set a $60.00 target price on Biohaven and gave the company a “buy” rating in a research report on Thursday, March 20th. Morgan Stanley cut their target price on shares of Biohaven from $69.00 to $63.00 and set an “overweight” rating for the company in a research note on Friday, March 7th. Royal Bank of Canada downgraded Biohaven from an “outperform” rating to a “sector perform” rating and lowered their price target for the stock from $54.00 to $21.00 in a research report on Monday, May 19th. Robert W. Baird lowered their price target on Biohaven from $60.00 to $57.00 and set an “outperform” rating on the stock in a research report on Monday, April 28th. Finally, William Blair raised Biohaven to a “strong-buy” rating in a research report on Thursday, April 24th. One investment analyst has rated the stock with a hold rating, twelve have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, Biohaven has an average rating of “Buy” and an average price target of $59.46.

Biohaven Stock Performance

NYSE:BHVN opened at $16.78 on Tuesday. The stock’s 50-day simple moving average is $18.34 and its 200 day simple moving average is $30.26. The company has a market cap of $1.71 billion, a P/E ratio of -1.79 and a beta of 0.95. Biohaven has a 52-week low of $14.33 and a 52-week high of $55.70.

Biohaven (NYSE:BHVN) last released its earnings results on Monday, May 12th. The company reported ($2.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.67) by ($0.50).

Hedge Funds Weigh In On Biohaven

Several institutional investors and hedge funds have recently made changes to their positions in BHVN. JPMorgan Chase & Co. grew its position in shares of Biohaven by 144.5% in the fourth quarter. JPMorgan Chase & Co. now owns 1,979,169 shares of the company’s stock valued at $73,922,000 after purchasing an additional 1,169,721 shares during the last quarter. Norges Bank acquired a new position in shares of Biohaven in the fourth quarter valued at approximately $33,711,000. Millennium Management LLC grew its position in shares of Biohaven by 1,172.9% in the first quarter. Millennium Management LLC now owns 901,258 shares of the company’s stock valued at $21,666,000 after purchasing an additional 830,457 shares during the last quarter. Farallon Capital Management LLC grew its position in shares of Biohaven by 21.6% in the fourth quarter. Farallon Capital Management LLC now owns 4,428,167 shares of the company’s stock valued at $165,392,000 after purchasing an additional 785,578 shares during the last quarter. Finally, Janus Henderson Group PLC grew its position in shares of Biohaven by 12.1% in the fourth quarter. Janus Henderson Group PLC now owns 6,982,425 shares of the company’s stock valued at $260,735,000 after purchasing an additional 756,032 shares during the last quarter. Institutional investors and hedge funds own 88.78% of the company’s stock.

Biohaven Company Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.